Zobrazeno 1 - 10
of 9 148
pro vyhledávání: ''
Publikováno v:
Nefrología. 42:671-679
To investigate the efficacy of combined immunosuppressive regimens of cyclosporine (CsA), tacrolimus (TAC), or cyclophosphamide (CTX) combined with steroids in the treatment of idiopathic membranous nephropathy (IMN).A total of 150 biopsy-proven IMN
Publikováno v:
Cancer Research and Treatment. 54:469-477
Purpose In hormone receptor-positive, human epidermal growth factor receptor 2–negative metastatic breast cancer (HR+ HER2–MBC), the mainstay treatment options include cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) and everolimus (EVE) in combi
Autor:
Britt J. Andersen, Vanga K Marius, Olivier Kouadio Kouadio, Charles W. Goss, Gary J. Weil, Allassane Ouattara, Catherine M. Bjerum, Daphne Lew, Meite Aboulaye, Benjamin G. Koudou, Christopher L. King
Publikováno v:
Clinical Infectious Diseases. 74:2200-2208
Background Ivermectin (IVM) plus albendazole (ALB), or IA, is widely used in mass drug administration (MDA) programs that aim to eliminate lymphatic filariasis (LF) in Africa. However, IVM can cause severe adverse events in persons with heavy Loa loa
Autor:
Emily Dotson, Narendranath Epperla, Kami J. Maddocks, Megan K Fleming, David A. Bond, Ying Huang, Lapo Alinari, Yazeed Sawalha, John C. Reneau, Beth Christian, Jonathan E. Brammer, Robert A. Baiocchi
Publikováno v:
Blood Advances
Key Points HDMTX administration on day 1 of (R)CHOP is feasible and compares favorably with reports of HDMTX administration midcycle.Delaying prophylactic HDMTX beyond cycle 1 of (R)CHOP might lower the risks of neutropenic fever and acute kidney inj
Autor:
Yoshiaki Murakami, Shingo Seo, Hiroyuki Otsuka, Yasushi Hashimoto, Naru Kondo, Shinya Takahashi, Takeshi Sudo, Kenjiro Okada, Tatsuaki Sumiyoshi, Kenichiro Uemura
Publikováno v:
European Journal of Cancer. 159:215-223
Background The prognosis of patients with borderline resectable pancreatic cancer with arterial contact (BRPC-A) is extremely poor, and effective preoperative treatment is indispensable. We evaluated the clinical efficacy and safety of neoadjuvant ch
Autor:
N. Zanaletti, Susana Roselló Keränen, Debora Ierinò, Riccardo Giampieri, Michele De Tursi, Fabio Gelsomino, Ingrid Garajová, Alessio Cortellini, P. Vitale, Pasquale Lombardi, Emanuela Dell'Aquila, Teresa Troiani, Silvana Leo, Andrea Spallanzani, Giampiero Porzio, Ilaria Depetris, Federica De Galitiis, Olga Venditti, Angelica Petrillo, Michela Roberto, Francesca Di Pietro, Corrado Ficorella, Olga Nigro, Michele Ghidini, Roberto Filippi, Giampaolo Tortora, Antonio Avallone, Katia Cannita, Nicola Tinari, Gian Paolo Spinelli, Cristina Morelli, Lisa Salvatore, Giacomo Aimar, Fulgenzi Claudia, Alessandro Parisi, M. Ribelli, Valeria Zurlo, Federica Zoratto, Carla D'Orazio
Publikováno v:
Clinical Colorectal Cancer
r-INCLIVA. Repositorio Institucional de Producción Científica de INCLIVA
instname
r-INCLIVA. Repositorio Institucional de Producción Científica de INCLIVA
instname
BACKGROUND: Doublets plus antiepidermal growth factor receptors monoclonal antibodies (EGFRi) are widely considered the preferable first-line regimen in patients with left-sided RAS/BRAF wild-type metastatic colorectal cancer (mCRC), resulting superi
Publikováno v:
Experimental and Clinical Transplantation. 19:1328-1333
OBJECTIVES With the standard regimen for graft-versushost disease prophylaxis in allogeneic stem cell transplant with human leukocyte antigen-matched donor, grade II-IV acute graft-versus-host disease occurs in 30% to 50% of sibling and up to 80% of
Autor:
Yang Zhu, Shu Tian, Hua Zhong, Wenhao Zhang, Lifeng Wang, Rong Tao, Zhi-Chao Li, Hao Ding, Lina Jin, Chuanying Zhu, Yu-Jie Ma, Chuan-xu Liu, Siguo Hao, Lan Xu
Publikováno v:
British Journal of Haematology. 196:939-946
Early-stage natural killer/T-cell lymphoma (NK/TCL) patients usually receive a combination of chemotherapy and radiotherapy, but the optimal treatment approach has not yet been established. This study aimed to investigate the efficacy and safety prof
Autor:
Bradley Curtis Carthon, Jesus Zoco, Thomas E. Hutson, Mark R. Olsen, Edward Arrowsmith, Johanna C. Bendell, Hamid Emamekhoo, Joshua Zhang, Daniel J. George, Scott S. Tykodi, David Leung, Ana M. Molina, Alexandra Drakaki, Lucio N. Gordan, Ivor John Percent, Daniel C. Cho, Jennifer L. Johansen, Arash Rezazadeh Kalebasty
Publikováno v:
Cancer. 128:966-974
Background Nivolumab plus ipilimumab (NIVO + IPI) has demonstrated long-term efficacy and safety in patients with previously untreated, advanced renal cell carcinoma (aRCC). Although most phase 3 clinical trials exclude patients with brain metastases
Autor:
Kohei Higuchi, Mariko Shimizu, Maho Koyama-Sato, Yosuke Okada, Masami Inoue, Shota Inoue, Kimitoshi Goto, Akihisa Sawada, Masahiro Yasui
Publikováno v:
International Journal of Hematology. 115:269-277
Graft failure is a major pitfall of unrelated umbilical cord blood transplantation (CBT) in children with rare hematological disorders other than acute leukemia, such as acquired and inherited bone marrow failure, myelodysplastic syndrome, juvenile m